1. Home
  2. LYFT vs ERAS Comparison

LYFT vs ERAS Comparison

Compare LYFT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyft Inc.

LYFT

Lyft Inc.

HOLD

Current Price

$13.73

Market Cap

5.4B

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$10.42

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYFT
ERAS
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.5B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
LYFT
ERAS
Price
$13.73
$10.42
Analyst Decision
Buy
Strong Buy
Analyst Count
29
12
Target Price
$20.07
$14.25
AVG Volume (30 Days)
13.1M
9.3M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
11250.00
36.23
EPS
0.04
N/A
Revenue
$6,316,261,000.00
N/A
Revenue This Year
$17.33
N/A
Revenue Next Year
$12.29
N/A
P/E Ratio
$346.63
N/A
Revenue Growth
9.16
N/A
52 Week Low
$12.46
$1.06
52 Week High
$25.54
$24.28

Technical Indicators

Market Signals
Indicator
LYFT
ERAS
Relative Strength Index (RSI) 43.32 36.76
Support Level $12.88 $2.07
Resistance Level $14.24 $16.14
Average True Range (ATR) 0.56 1.29
MACD -0.07 -0.55
Stochastic Oscillator 22.01 11.04

Price Performance

Historical Comparison
LYFT
ERAS

About LYFT Lyft Inc.

Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: